Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

OSE Immunotherapeutics SA (ORPOF) Price & Analysis

ORPOF Stock Chart & Stats

$4.43$0.00(0.00%)
At close: 4:00 PM EDT
No data to display
Day’s Range
$4.43 - $4.43
52-Week Range
$4.43 - $11.60
Previous Close
$4.43
Volume
N/A
Average Volume (3M)
0
Market Cap
$51.46M
Enterprise Value
$128.21M
Total Cash (Recent Filing)
$22.65M
Total Debt (Recent Filing)
$35.38M
Price to Earnings (P/E)
―
Beta
0.40
Next Earnings
Mar 31, 2027
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Prior-year Operating Strength

The company demonstrated that its development and partnering model can generate substantial revenue and profitability under favorable conditions. Although performance later weakened, the 2024 result provides evidence of commercial potential and an ability to convert successful programs or transactions into meaningful operating value.

Historical Cash Generation

Strong positive operating and free cash flow in 2024 shows that OSE has previously been capable of producing internal funding from its activities. That history supports the potential to finance research and development without relying exclusively on external capital when operating results and program economics are favorable.

Improved Leverage Versus 2023

Balance-sheet leverage is still substantial, but the improvement from 2023 indicates some progress in reducing relative financial pressure. This provides a stronger starting point for capital allocation and partnership discussions than the earlier capital structure, provided the company can prevent further equity erosion.

Bears Say

Severe Revenue Contraction

The dramatic revenue decline indicates that recent operating performance is highly dependent on irregular program or transaction outcomes rather than a steadily compounding commercial base. A very small revenue platform reduces funding capacity for clinical development and makes future results unusually sensitive to individual milestones.

Large Losses And Unstable Earnings

A large net loss combined with deeply negative operating profitability places sustained pressure on the company’s capital base. Unless operating performance improves, ongoing research and development will need to be supported by financing, partnerships, or other non-operating sources, limiting strategic flexibility.

Cash-burn And Funding Dependence

The reversal from strong positive cash generation in 2024 to substantial cash burn in 2025 materially increases dependence on external funding. Persistent negative free cash flow could constrain clinical investment, increase financing requirements, and amplify dilution or other capital-raising pressure over coming quarters.

OSE Immunotherapeutics SA News

ORPOF FAQ

What was OSE Immunotherapeutics SA’s price range in the past 12 months?
OSE Immunotherapeutics SA lowest stock price was $4.43 and its highest was $11.60 in the past 12 months.
What is OSE Immunotherapeutics SA’s market cap?
OSE Immunotherapeutics SA’s market cap is $51.46M.
When is OSE Immunotherapeutics SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were OSE Immunotherapeutics SA’s earnings last quarter?
OSE Immunotherapeutics SA released its earnings results on Apr 30, 2026. The company reported -$1.131 earnings per share for the quarter.
Is OSE Immunotherapeutics SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does OSE Immunotherapeutics SA pay dividends?
OSE Immunotherapeutics SA does not currently pay dividends.
What is OSE Immunotherapeutics SA’s EPS estimate?
OSE Immunotherapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OSE Immunotherapeutics SA have?
OSE Immunotherapeutics SA has 23,560,110 shares outstanding.
What happened to OSE Immunotherapeutics SA’s price movement after its last earnings report?
OSE Immunotherapeutics SA reported an EPS of -$1.131 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of OSE Immunotherapeutics SA?
Currently, no hedge funds are holding shares in ORPOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology